Vivacta Biotechnology
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
$50MSeries A+
Role not disclosedLV
Loyal Valley Capital
Activity from announced rounds
Activity in this selectionmario-wettengel-1fd25234
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $50M 1 disclosed · full round size, not this investor’s share